RT Book, Section A1 DaSilva, Marcelo C. A1 Sugarbaker, Paul A1 Sugarbaker, David J. A2 Sugarbaker, David J. A2 Bueno, Raphael A2 Colson, Yolonda L. A2 Jaklitsch, Michael T. A2 Krasna, Mark J. A2 Mentzer, Steven J. A2 Williams, Marcia A2 Adams, Ann SR Print(0) ID 1105845474 T1 Intracavitary Hyperthermic Chemotherapy for Malignant Mesothelioma T2 Adult Chest Surgery, 2e YR 2015 FD 2015 PB McGraw-Hill Education PP New York, NY SN 978-0-07-178189-3 LK accesssurgery.mhmedical.com/content.aspx?aid=1105845474 RD 2023/02/07 AB The rising incidence of malignant mesothelioma worldwide has intensified the search for treatment strategies to extend disease-free survival.1 To date, the best survival has been observed in patients undergoing multimodality therapy with surgery, either extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D), plus chemotherapy and/or radiation therapy.2–7 Seminal work at the Washington Cancer Center and Brigham and Women's Hospital led to the development of innovative surgical techniques to accomplish macroscopic complete resection, along with intracavitary lavage with hyperthermic platinum-based chemotherapy for local control. The rationale for hyperthermic intraoperative thoracoabdominal chemotherapy has been previously described, with particular emphasis on malignant peritoneal mesothelioma.8 This chapter describes the thoracic delivery of heated intraoperative chemotherapy for patients with malignant pleural mesothelioma (MPM), along with special advice on perioperative pitfalls and complications.